TY - JOUR
T1 - CRISPR-based engineering of next-generation lactic acid bacteria
AU - Hidalgo-Cantabrana, Claudio
AU - O'Flaherty, Sarah
AU - Barrangou, Rodolphe
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/6
Y1 - 2017/6
N2 - The advent of CRISPR-based technologies has opened new avenues for the development of next-generation food microorganisms and probiotics with enhanced functionalities. Building off two decades of functional genomics studies unraveling the genetic basis for food fermentations and host–probiotic interactions, CRISPR technologies offer a wide range of opportunities to engineer commercially-relevant Lactobacillus and Bifidobacteria. Endogenous CRISPR–Cas systems can be repurposed to enhance gene expression or provide new features to improve host colonization and promote human health. Alternatively, engineered CRISPR–Cas systems can be harnessed to genetically modify probiotics and enhance their therapeutic potential to deliver vaccines or modulate the host immune response.
AB - The advent of CRISPR-based technologies has opened new avenues for the development of next-generation food microorganisms and probiotics with enhanced functionalities. Building off two decades of functional genomics studies unraveling the genetic basis for food fermentations and host–probiotic interactions, CRISPR technologies offer a wide range of opportunities to engineer commercially-relevant Lactobacillus and Bifidobacteria. Endogenous CRISPR–Cas systems can be repurposed to enhance gene expression or provide new features to improve host colonization and promote human health. Alternatively, engineered CRISPR–Cas systems can be harnessed to genetically modify probiotics and enhance their therapeutic potential to deliver vaccines or modulate the host immune response.
UR - http://www.scopus.com/inward/record.url?scp=85020738237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020738237&partnerID=8YFLogxK
U2 - 10.1016/j.mib.2017.05.015
DO - 10.1016/j.mib.2017.05.015
M3 - Review article
C2 - 28622636
AN - SCOPUS:85020738237
SN - 1369-5274
VL - 37
SP - 79
EP - 87
JO - Current Opinion in Microbiology
JF - Current Opinion in Microbiology
ER -